HOME >> MEDICINE >> NEWS
Higher doses of cancer drug imatinib proven effective and safe

ortance as previous studies of another cancer drug (interferon alpha) have shown that CCR is associated with a 70 to 80 percent chance of 10-year survival, a positive prospect as the survival time for newly diagnosed CML patients is typically about five years.

Another measure of successful treatment is the number of patients with complete molecular response, occurring when the levels of BCR-ABL are so low that they are undetectable using a highly sensitive method called polymerase chain reaction. In past studies, patients who had undetectable levels of BCR-ABL after treatment have not relapsed after long-term follow up. In high-dose therapy patients, the incidence of complete molecular response was 28 percent compared to only seven percent of patients taking the standard dosage of imatinib.

"The high rates of complete cytogenetic and molecular response that we've seen in this study are unprecedented. If such responses have similar long-term significance as seen in previous studies, this translates into a major improvement in the prognosis of patients with CML," states Hagop Kantarjian, M.D., chairman of the Department of Leukemia at M. D. Anderson Cancer Center and the lead author of the study.

Researchers found that the high dosage of imatinib was generally well tolerated, with a similar rate of side effects as standard dose imatinib. To reduce more severe side effects, the dosage of imatinib was lowered to 600 mg or 400 mg daily for some patients, though a majority remained at the target dosage.

The disease did not transform beyond the chronic phrase in any of the study patients, and 98 percent had a complete hematologic response, meaning the number of white blood cells was no longer out of control and the signs and symptoms of leukemia were gone.

The results of the study indicate that patients in the early stage of this cancer may benefit from higher doses of the drug imatinib in their initial treatment to safely and effe
'"/>

Contact: Aislinn Raedy
araedy@hematology.org
202-776-0544
American Society of Hematology
1-Apr-2004


Page: 1 2 3

Related medicine news :

1. Higher folate intake associated with decreased risk of hypertension in women
2. Higher incidence of rejection following early steroid withdrawal
3. Higher radiation doses help some lung cancer patients live longer
4. Higher dose of Gleevec leads to increased remission in CML patients
5. Higher education or larger brain size may protect against dementia later in life, new study finds
6. Higher cost sharing reduces plans drug expenditures, but boosts enrollee costs
7. Higher nocturnal blood pressure predictive of kidney disease in diabetes
8. First quarter 2002 prescription drug spending: Higher again, but rate of increase drops
9. Higher rate of improvement, lower rate of adverse effects with clarithromycin for acute exacerbations of chronic bronchitis
10. Cancer Rates In Children Of Nuclear Industry Employees No Higher Than General Population In England And Wales
11. New Study Finds Blacks Face 38 Percent Higher Stroke Risk

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Higher doses cancer drug imatinib proven effective and safe

(Date:5/5/2015)... May 05, 2015 The Florida ... Hospital Tampa has been recognized by the National ... 4 Epilepsy Center. The role of a specialized ... of a patient’s seizure type and seizure syndrome, ... appropriate treatment specific to a patient’s diagnosis and ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 NCPDP announced ... Partner Program. The program establishes a three-year commitment of ... maximum of 10 Elite Partners. “AmerisourceBergen has supported our ... President of NCPDP, “and this is a wonderful continuation ... , We can trace AmerisourceBergen back to our very ...
(Date:5/5/2015)... 05, 2015 Hiliary Critchley, Senior ... present at the 24th Annual WEDI National ... MT in Scottsdale, AZ. WEDI, the Workgroup for ... authority on the use of health IT to ... National Director of Telemedicine for UnitedHealthcare will co-present ...
(Date:5/5/2015)... Dallas, TX (PRWEB) May 05, 2015 ... has selected C.R. Bard Inc., a leading multinational ... technologies in the fields of vascular, urology, oncology ... its 2015 Vanguard Award. The Vanguard Award ... of employee wellness programs among Viverae’s significant client ...
(Date:5/5/2015)... CA (PRWEB) May 05, 2015 Nutritional ... and actually prevent a variety of health conditions and ... this modern research to adopt clean eating methods to ... artificial dyes associated with over-consumption of fast and processed ... plans easy to follow and report feeling better ...
Breaking Medicine News(10 mins):Health News:Florida Hospital Tampa Epilepsy Program Earns Designation as a Level 4 Epilepsy Center by the National Association of Epilepsy Centers (NAEC) 2Health News:AmerisourceBergen Joins NCPDP Elite Partner Program 2Health News:AmerisourceBergen Joins NCPDP Elite Partner Program 3Health News:Optimity Advisors’ Hiliary Critchley, Telemedicine Expert, to Speak at WEDI Conference May 20th in Scottsdale, AZ 2Health News:Viverae® Honors C. R. Bard, Inc. with 2015 Vanguard Award 2Health News:Diet Doc Introduces Diet Plans that Teach Patients how to Eat Clean by Getting Back to Basics and Exchanging Processed Foods for Clean, Nutritious Foods 2Health News:Diet Doc Introduces Diet Plans that Teach Patients how to Eat Clean by Getting Back to Basics and Exchanging Processed Foods for Clean, Nutritious Foods 3
(Date:5/5/2015)... , May 5, 2015 Ardelyx, Inc. ... focused on cardio-renal, gastrointestinal, and metabolic diseases, today ... evaluating tenapanor in Stage 3 chronic kidney disease ... did not meet the primary endpoint of decreasing ... to patients receiving placebo. Ardelyx ...
(Date:5/5/2015)... 2015 (Family Features) Which health screenings and ... most adults, monitoring your weight, cholesterol, and blood pressure ... what about vision care? Photo - ... their 40s, they often start to notice small changes ... and job performance. Whether having difficulty reading a book ...
(Date:5/5/2015)... May 05, 2015 Research and Markets ... of the "Electro Surgical Market" report ... market is expected to achieve a CAGR of ... offer huge benefits for patients as well as ... infections, condensed visible marks, bleeding control and improved ...
Breaking Medicine Technology:Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 2Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 3Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 4Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 5Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 6Eye Care as You Age 2Eye Care as You Age 3Eye Care as You Age 4Global Electro Surgical Market 2015 2
Cached News: